['healthy']
['ly3192767', 'basal insulin peglispro', 'insulin glargine', 'placebo']

        Inclusion Criteria:

          -  Are overtly healthy males or females, as determined by medical history and physical
             examination

          -  Have a body mass index (BMI) of >18.5 and <30.0 kilogram per square meter (kg/m²),
             inclusive

        Exclusion Criteria:

          -  Are currently enrolled in a clinical trial involving an investigational product or any
             other type of medical research judged not to be scientifically or medically compatible
             with this study

          -  Have participated, within the last 30 days, in a clinical trial involving an
             investigational product. If the previous investigational product has a long half-life,
             3 months or 5 half-lives (whichever is longer) should have passed

          -  Have participated as a participant in a first-in-human study within 90 days of the
             initial dose of study drug

          -  Have known allergies to insulin, heparin, or related drugs, or history of relevant
             allergic reactions of any origin

          -  Have a history or presence of cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine, hematological, chronic inflammatory disease, or
             neurological disorders capable of significantly altering the absorption, metabolism,
             or elimination of drugs; of constituting a risk when taking the study medication; or
             of interfering with the interpretation of data
      